BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38576220)

  • 1. Quality of life improvements in women with uterine fibroids treated with relugolix combination therapy during the LIBERTY long-term extension study: A descriptive subgroup analysis in women with anemia at baseline.
    Venturella R; Lukes AS; Wu R; McLean R; Rakov VG; Al-Hendy A
    Int J Gynaecol Obstet; 2024 May; 165(2):431-441. PubMed ID: 38576220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study.
    Stewart EA; Al-Hendy A; Lukes AS; Madueke-Laveaux OS; Zhu E; Proehl S; Schulmann T; Marsh EE
    Am J Obstet Gynecol; 2024 Feb; 230(2):237.e1-237.e11. PubMed ID: 37863160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials.
    Stewart EA; Lukes AS; Venturella R; Li Y; Hunsche E; Wagman RB; Al-Hendy A
    Am J Obstet Gynecol; 2023 Mar; 228(3):320.e1-320.e11. PubMed ID: 36370871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas.
    Al-Hendy A; Lukes AS; Poindexter AN; Venturella R; Villarroel C; McKain L; Li Y; Wagman RB; Stewart EA
    Obstet Gynecol; 2022 Dec; 140(6):920-930. PubMed ID: 36357960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LIBERTY randomized withdrawal study: relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids.
    Al-Hendy A; Venturella R; Arjona Ferreira JC; Li Y; Soulban G; Wagman RB; Lukes AS
    Am J Obstet Gynecol; 2023 Dec; 229(6):662.e1-662.e25. PubMed ID: 37666383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy.
    Al-Hendy A; Lukes AS; Poindexter AN; Venturella R; Villarroel C; Critchley HOD; Li Y; McKain L; Arjona Ferreira JC; Langenberg AGM; Wagman RB; Stewart EA
    N Engl J Med; 2021 Feb; 384(7):630-642. PubMed ID: 33596357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A plain language summary of the long-term relugolix combination therapy study for uterine fibroids.
    Al-Hendy A; Lukes AS; Venturella R; Villarroel C; McKain L; Li Y; Wagman RB; Stewart EA
    J Comp Eff Res; 2023 Aug; 12(8):e230069. PubMed ID: 37477173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials.
    Stewart EA; Lukes AS; Venturella R; Arjona Ferreira JC; Li Y; Hunsche E; Wagman RB; Al-Hendy A
    Obstet Gynecol; 2022 Jun; 139(6):1070-1081. PubMed ID: 35675604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relugolix combination therapy in European women with symptomatic uterine fibroids: a subgroup analysis from the randomized phase 3 LIBERTY pivotal trials.
    Venturella R; Rechberger T; Zatik J; Wagman RB; Zhu E; Rakov VG; Petraglia F
    Gynecol Endocrinol; 2023 Aug; 39(1):2249107. PubMed ID: 37634528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A plain language summary of the safety of relugolix combination therapy and improvement in symptoms in women with uterine fibroids from the LIBERTY 1 and LIBERTY 2 studies.
    Al-Hendy A; Lukes AS; Poindexter AN; Venturella R; Villarroel C; Critchley HO; Li Y; McKain L; Arjona Ferreira JC; Langenberg AG; Wagman RB; Stewart EA
    Pain Manag; 2023 Apr; 13(4):205-211. PubMed ID: 37183454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids.
    Syed YY
    Drugs; 2022 Oct; 82(15):1549-1556. PubMed ID: 36331779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas: A Randomized Controlled Trial.
    Osuga Y; Enya K; Kudou K; Tanimoto M; Hoshiai H
    Obstet Gynecol; 2019 Mar; 133(3):423-433. PubMed ID: 30741797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study.
    Becker CM; Johnson NP; As-Sanie S; Arjona Ferreira JC; Abrao MS; Wilk K; Imm SJ; Mathur V; Perry JS; Wagman RB; Giudice LC
    Hum Reprod; 2024 Mar; 39(3):526-537. PubMed ID: 38243752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An evaluation of relugolix/estradiol/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
    Ali M; Chen HY; Chiang YF; Badary OA; Hsia SM; Al-Hendy A
    Expert Opin Pharmacother; 2022 Mar; 23(4):421-429. PubMed ID: 35068291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials.
    Stewart EA; Diamond MP; Williams ARW; Carr BR; Myers ER; Feldman RA; Elger W; Mattia-Goldberg C; Schwefel BM; Chwalisz K
    Hum Reprod; 2019 Apr; 34(4):623-634. PubMed ID: 30865281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
    Murji A; Whitaker L; Chow TL; Sobel ML
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010770. PubMed ID: 28444736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a Phase III, randomized, multicenter, double-blind, controlled trial.
    Muneyyirci-Delale O; Richard-Davis G; Morris T; Armstrong J
    Clin Ther; 2007 Aug; 29(8):1682-91. PubMed ID: 17919549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relugolix for the treatment of uterine fibroids.
    Rocca ML; Palumbo AR; Lico D; Fiorenza A; Bitonti G; D'Agostino S; Gallo C; Di Carlo C; Zullo F; Venturella R
    Expert Opin Pharmacother; 2020 Oct; 21(14):1667-1674. PubMed ID: 32674616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical trial of alternative relugolix administration for uterine leiomyoma prior to surgically treatment: a study protocol for Non-Adverse Relugolix Administration (NARA) trial.
    Kawahara N; Kawaguchi R; Yamamoto K; Nishikawa K; Matsuoka M; Maehana T; Fukui Y; Yamanaka S; Sugimoto S; Iwai K; Yamada Y; Kurakami H; Hirata T; Takashima R; Suzuki S; Asada K; Kasahara M; Kimura F
    Trials; 2024 Jan; 25(1):68. PubMed ID: 38243317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term health-related quality of life and symptom severity following hysterectomy, myomectomy, or uterine artery embolization for the treatment of symptomatic uterine fibroids.
    Anchan RM; Spies JB; Zhang S; Wojdyla D; Bortoletto P; Terry K; Disler E; Milne A; Gargiulo A; Petrozza J; Brook O; Srouji S; Morton CC; Greenberg J; Wegienka G; Stewart EA; Nicholson WK; Thomas L; Venable S; Laughlin-Tommaso S; Diamond MP; Maxwell GL; Marsh EE; Myers ER; Vines AI; Wise LA; Wallace K; Jacoby VL
    Am J Obstet Gynecol; 2023 Sep; 229(3):275.e1-275.e17. PubMed ID: 37244458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.